Last reviewed · How we verify
bivalent rLP2086
bivalent rLP2086 is a vaccine that targets the SARS-CoV-2 spike protein.
bivalent rLP2086 is a vaccine that targets the SARS-CoV-2 spike protein. Used for Prevention of COVID-19 in individuals 12 years of age and older.
At a glance
| Generic name | bivalent rLP2086 |
|---|---|
| Sponsor | Pfizer |
| Drug class | vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
It is designed to provide broad protection against COVID-19 by eliciting a strong immune response against the virus. The bivalent design allows it to target two different variants of the spike protein, potentially offering protection against multiple strains of the virus.
Approved indications
- Prevention of COVID-19 in individuals 12 years of age and older
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants (PHASE2)
- A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age. (PHASE3)
- A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years (PHASE2)
- A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years. (PHASE2)
- Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers. (PHASE2)
- A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years (PHASE2)
- Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose (PHASE3)
- A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bivalent rLP2086 CI brief — competitive landscape report
- bivalent rLP2086 updates RSS · CI watch RSS
- Pfizer portfolio CI